Serguei Soukharev
Astellas Pharma (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Cancer Research and Treatments, Cancer, Hypoxia, and Metabolism, Cancer Immunotherapy and Biomarkers, Cancer Cells and Metastasis
Most-Cited Works
- → Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas(2016)95 cited
- → Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm(2020)70 cited
- → Segmental genomic replacement in embryonic stem cells by double lox targeting(1999)69 cited
- → Expression of Factor VIII in Recombinant and Transgenic Systems(2002)35 cited
- → Failure of immunocompetitive capillary electrophoresis assay to detect disease‐specific prion protein in buffy coat from humans and chimpanzees with Creutzfeldt‐Jakob disease(2003)33 cited
- → The Use of the Uromodulin Promoter to Target Production of Recombinant Proteins into Urine of Transgenic Animals(2002)23 cited
- → Uromodulin promoter directs high-level expression of biologically active human α1-antitrypsin into mouse urine(2002)22 cited
- → A fluorogenic substrate for detection of organophosphatase activity(2004)19 cited
- → Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas.(2016)5 cited
- → Functional identification of novel activities: Activity-based selection of proteins from complete proteomes(2007)4 cited